Drug therapy in peptic ulcer disease by Debas, Haile T. & Mulholland, Michael W.
DRUG THERAPY IN PEPTIC ULCER 
DISEASE 
The treatment of peptic ulcer disease has undergone a revolution 
in the past decade. This revolution, based on advances in cellular 
biology, pharmacology, and health care delivery, has changed forever 
the treatment of this major disease. An improved understanding of 
the regulation and cellular mechanisms of gastric acid secretion has 
resulted in the development of specific and potent drugs for the 
treatment of peptic ulcer. These new agents permit clinicians to af- 
fect, at specific points, the abnormal secretory and mucosal defense 
mechanisms associated with peptic ulceration. 
Of the new agents, the histamine Hz-receptor antagonists are cur- 
rently the most important. While the incidence of peptic ulcer has 
been declining in the United States since the mid 196Os, the intro- 
duction of effective Hz-receptor antagonists led to a further, precipi- 
tous fall in patients referred for elective peptic ulcer surgery. tntract- 
ability as an indication for operative therapy has become 
exceedingly rare. Indeed, the circumstances that constitute failure of 
medical therapy or are indications for surgical therapy in this cimet- 
idine era have yet to be clearly defined. 
The contribution of the Hz-receptor antagonists and other newer 
antisecretory drugs to the improved treatment of patients with pep- 
tic ulcer disease cannot be overestimated, and yet, future improve- 
ments appear likely. An important milestone in the development of 
potent antisecretory drugs may have been achieved with the synthe- 
sis of proton-pump inhibitors. As will be discussed, the evidence is 
unequivocal that these new agents effectively relieve ulcer pain, pro- 
mote healing, and reduce short-term ulcer morbidity. It must be 
pointed out, however, that none of the antisecretory drugs devel- 
oped to date have been shown to alter the natural history of peptic 
ulcer disease, i.e., the ulcer diathesis. Currently available agents are 
essentially palliative; they promote healing of ulcers but do not cure 
ulcer disease. The next important milestone in the treatment of pep- 
tic ulcer disease will be the discovery of drugs which permanently 
alter the ulcer diathesis. 
The purposes of this presentation will be: (11 to discuss the regu- 
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lation and cellular mechanisms of acid secretion; (2) to classify drugs 
used in ulcer therapy according to their sites and mechanisms of 
action; (3) to discuss the important drugs with respect to their phar- 
macokinetics, clinical efficacy, and side effects; and (4) to provide a 
perspective for use of the various agents in peptic ulcer disease and 
to examine the present and future impact of new drugs on surgery 
for peptic ulcer disease. 
REGULATION OF GASTRIC ACID SECRETION 
Gastric acid secretion is regulated through a complex interaction 
of nerves, hormones, and local or paracrine agents (Fig 11. Gastric 
acid is produced by specialized parietal cells contained in the 
fundic mucosa. Parietal cells secrete hydrochloric acid via the ac- 
tions of a unique hydrogen-potassium ATPase into the secretory 
canaliculus, an infolding of the plasma membrane which, in turn, 

















Regulation of gastric acid secretion. NT-neurotensin; PYY-peptide YY 
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communicates with the gastric lumen. These neurohumoral mech- 
anisms serve to modulate both inhibitory and stimulatory pro- 
cesses.l The human stomach normally contains about 1 billion pa- 
rietal cells. The parietal cell secretes acid continuously both in the 
basal and fasting state. The mechanisms underhying this basal acid 
secretion are poorly understood. In general, we have a better under- 
standing of the processes that stimulate acid secretion than of those 
that inhibit it. 
BASAL ACID SECRETION 
The normal human stomach secretes 2 to 5 mEq of HCI per hour 
in the fasting state. Since vagotomy decreases this basal secretion by 
some 85%, it has been presumed that vagal tone is important in 
determining the rate of basal acid production. However, Hz-receptor 
blockers have also been demonstrated to inhibit basal acid secretion 
by about 80%. One might conclude, therefore, that ambient hista- 
mine concentration in the interstitial fluid bathing the parietal cell 
as well as vagal tone are important in sustaining basal acid secretion. 
Gastrin does not appear to play an important role in basal acid se- 
cretion in normal individuals. Patients with the Zollinger-Ellison 
syndrome, however, may secrete in excess of 10 mEq of acid per 
hour in the fasting state and, in this pathological condition, basal 
acid secretion is stimulated by gastrin. Critically ill patients, partic- 
ularly those who are septic or have increased intracranial pressure, 
will also have increased “basal” acid secretion. 
STIMULATED ACID SECRETION 
Phasic vagal discharge in response to the thought, sight, or smell 
of food stimulates acid secretion directly by a cholinergic mecha- 
nism. Vagal discharge also inhibits gastric somatostatin release. 
Since somatostatin inhibits parietal cell secretion, inhibition of so- 
matostatin release may be an additional mechanism by which the 
vagus stimulates acid secretion. The direct cholinergic action of the 
parietal cell has the more important role, however. The cephalic 
phase component of acid secretion, as determined by sham-feeding 
of normal individuals, is about 10 mEq/hr. This vagally controlled 
component of acid secretion represents approximately 40% of the 
maximal acid response to gastrin infusion. 
When food enters the stomach, distention triggers neural reflexes 
and gastrin release is activated. A technique of continuous intragas- 
tric titration can be used to estimate the amount of acid the stomach 
secretes in response to a meal. These estimates range from 15 to 25 
mEq/hr, or approximately 75% of maximal response to exogenous 
gastrin or histamine. The reason that the maximal response to a 
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meal is somewhat lower than the response to exogenous stimulants 
may be the concomitant release of somatostatin by food. 
Gastrin is the most important mediator of the gastric phase of acid 
secretion. It is of interest that women secrete twice as much gastrin 
as men in response to food. Since their meal-stimulated acid re- 
sponse is equal to or less than that of men, the parietal cells in 
women may be less sensitive to gastrin. The reason for these differ- 
ences is unknown. 
When food enters the small intestine, an additional mechanism 
for acid secretion is activated. The “intestinal phase hormone” OI 
“enterooxyntin” is released. Purification and chemical characteriza- 
tion of this putative hormone has not been accomplished. Physiolog- 
ical studies suggest that although enterooxyntin is a weak stimulant 
of acid secretion, it is capable of markedly augmenting the acid re- 
sponse to both submaximal and maximal doses of gastrin and his- 
tamine. 
INHIBITION OF ACID SECBETION 
Inhibitor?/ regulation of gastric acid secretion is accomplished 
through central, vagal, gastric, intestinal, and colonic mechanisms. A 
number of neuropeptides, most importantly bombesin or gastrin-re- 
leasing peptide, cause profound inhibition of gastric acid secretion 
when administered into the lateral cerebral ventricles of rats and 
dogs. Whether these centrally inhibiting neuropeptides play a phys- 
iological role in inhibiting the regulation of acid secretion in humans 
has not been established. The vagus appears to exert a dual control 
of acid secretion and gastrin release, modulating both stimulatory 
and inhibitory actions. After vagotomy, fasting and postprandial 
plasma gastrin levels increase, indicating that the vagus normally ex- 
erts tonic inhibitory regulation on gastrin release. The vagal fibers to 
the oxyntic mucosa appear to mediate this inhibition. In animals, 
sham-feeding inhibits pentagastrin-stimulated acid secretion, imply- 
ing that vagal activation by sham-feeding causes the release of an 
inhibitory substance. The imputed vagal inhibitor has been referred 
to as “vagogastrone.” 
The inhibition of gastric acid secretion relies on negative feedback 
inhibition of gastrin release by acid and on other neurohumoral 
mechanisms. When gastric pH falls to 2.0, gastrin release ceases. So- 
matostatin may be an important mediator of this negative feedback 
loop. In addition, somatostatin is a dominant paracrine agent within 
the gastric wall to modulate both the release of gastrin from the 
antrum and the secretion of HC from the oxyntic mucosa. The re- 
lease of somatostatin is reciprocally linked to that of gastrin; stimu- 
lation of somatostatin release is associated with inhibition of gastrin 
release. Other neuropeptides, contained within vagal fibers in the 
gastric wall, may also play an inhibitory role. Calcitonin-gene-related 
peptide and substance P are two of many neuropeptides which may 
be important in modulating acid secretion. Additionally, other neu- 
roendocrine substances, whose release from the oxyntic mucosa are 
under vagal control, may subserve inhibitory functions. Ulcer recur- 
rence after proximal gastric vagotomy has been postulated to be 
partly due to interference in the release of these inhibitors of acid 
secretion. 
Intestinal phase inhibition occurs when acid, fat, and hyperos- 
molar solutions enter the intestine. Acid in the upper intestine re- 
leases secretin and another inhibitory agent (bulbogastrone) from 
the duodenal bulb. High doses of secretin have been demonstrated 
to inhibit gastric acid secretion, although there is some debate as to 
whether secretin plays a physiologically-important inhibitory role 
during normal digestion. Other inhibitory peptides released from the 
small intestine include gastric inhibitory peptide, somatostatin, neu- 
rotensin, and peptide YY (PYY). Each of these agents has been dem- 
onstrated to inhibit acid secretion. PYY and another humoral agent 
yet to be isolated tcologastronel are also released from the colonic 
mucosa. It is possible that all of the intestinal and colonic inhibitors 
act synergistically to turn off acid secretion after a meal. 
CELLULAR MECHANISMS OF ACID SECRETION 
Three “on switches” are present in the basolateral membrane of 
the acid-secreting parietal cell (Fig 2). These are specific receptors 
for histamine, acetylcholine, and gastrin.’ When histamine occupies 
the HZ-receptor, a membrane-bound enzyme, adenylate cyclase, is 
activated. This activated enzyme converts ATP into cyclic AMP, 
which then acts as the secondary, intracellular messenger. Increased 
intracellular cyclic AMP results in a cascade of intracellular events 
including, sequentially, activation of protein-C kinase, protein phos- 
phorylation, and stimulation of the H+-Kf -ATPase proton pump, lo- 
cated on the secretory or canalicular membrane of the parietal cell. 
The proton pump is a unique enzyme system in the plasma mem- 
brane of the parietal cell, which causes the secretion of H’ into the 
lumen of the secretory canaliculus in exchange for K+ against a 
steep electrochemical gradient. Within the secretory canaliculus, the 
pH approximates 1. This process represents the final common path- 
way by which all stimulants affect acid secretion. 
When acetylcholine and gastrin occupy their respective receptors, 
the initial cascade of intracellular events activated is different. In this 
case, membrane bound phosphoproteins are activated resulting in 
the conversion of phosphoinositoldiphosphate (PIP,) to inositoltri- 
phosphate (IPJ and diacylglycerol. The main action of IP3 is to in- 
crease intracellular calcium, initially by mobilization of calcium as- 












Cellular mechanism of acid secretion. H-histamine; G-gastrin; DAG-diacylglycerol. 
sociated with the rough endoplasmic reticulum and later by influx 
of extracellular calcium. Thus, calcium is the secondary intracellular 
messenger for the actions of gastrin and acetylcholine. Different pro- 
tein-kinases are subsequently activated for gastrin or acetylcholine, 
but the final steps of phosphorylation and activation of the H+-K+- 
ATPase are probably the same for both agents. 
It is clear that several classes of drugs that specifically inhibit acid 
secretion could be developed: those that block the cell-surface re- 
ceptors for histamine, gastrin, or acetylcholine, those that interfere 
with intracellular processes, and, finally, those that block the proton 
pump. Receptor antagonists for histamine, gastrin, or acetylcholine 
and proton pump inhibitors would be expected to have important 
advantages in terms of specificity. The revolution in therapy for pa- 
tients with peptic ulcer has occurred because of the availability of 
drugs with these characteristics. However, since similar intracellular 
pathways are utilized by many tissues for generation of second mes- 
sengers and for intracellular protein phosphotylation, it is unlikely 
that drugs that selectively inhibit the intracellular processes of the 
parietal cell will have clinical utility. Figure 3 depicts the drugs used 
in peptic ulcer therapy according to their site of action. 
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FIG 3. 
Drugs used in peptlc ulcer therapy classlfled according to site of action. H-histamine; G- 
gastrin Ach-acetylchollne. 
PATHOPHYSIOLOGY OF PEPTIC ULCER DISEASE 
EPIDEMIOLOGY 
The incidence of peptic ulcer disease has been declining in the 
United States for the past 3 decades. The data which support this 
contention come from studies of military personnel, from the Veter- 
ans Administration, and from physician surveys.3-5 The reasons for 
the declining incidence of peptic ulcer disease are unknown. The 
treatment of peptic ulcer disease has also undergone a radical 
change, becoming less hospital-oriented. In the decade from 1970 to 
1980, hospital admissions for the treatment of duodenal ulcer 
dropped by 40% ;’ this drop was broadly paralleled by falling ulcer- 
related mortality rates. 
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When examined more closely, however, the trends are not uni- 
formly encouraging. While duodenal ulcer admissions have declined 
sharply for men, they have risen for women.’ By 1981, the prevalence 
of duodenal ulcer in men and women was equal, erasing a long- 
standing male predominance. The reasons for these shifting patterns 
of duodenal ulceration are not known; however, changes in individ- 
ual exposure to ulcerogenic environmental factors have been sug- 
gested. In this regard, cigarette smoking is a major risk factor for 
duodenal ulcer development and recurrence. Accordingly, hospital- 
ization and mortality rates for patients who smoke have a pattern 
similar to those for patients with duodenal ulcer.8 Cigarette smoking 
has declined in American men in the past 20 years and only slightly 
or not at all in women during the same period.Y Currently, an equal 
proportion of middle-aged men and women, the age range most at 
risk for peptic ulcer disease, smoke cigarettes. 
Although the clinical use of HZ-receptor antagonists cannot ex- 
plain changing rates of duodenal ulceration, these drugs have had a 
major influence on the treatment of patients with established ulcers. 
Specifically, the use of cimetidine has had an enormous impact on 
surgical practice. In both the United States and the United Kingdom, 
the already-declining operative rates for peptic ulcer disease, reflect- 
ing generally the declining incidence of the disease, were further 
decreased by the widespread use of powerful HZ-receptor antago- 
nists.l’, l1 There was a virtual elimination of operations performed for 
intractability. By contrast, operative rates for complicated ulcer dis- 
ease, e.g., perforation or hemorrhage, have remained largely un- 
changed to the present. 
PHYSIOLOGZCX ABNORMALITIES 
A number of physiological abnormalities have been demonstrated 
in patients with duodenal ulcer disease; however, a single causative 
defect has not been elucidated, reflecting the complexity and the 
probable heterogeneity of the disease process. Investigations of the 
pathophysiology of duodenal ulcer have focused on three general 
areas: abnormalities of gastric acid secretion, defects in endocrine 
control mechanisms, and deficits in mucosal resistance to acid. 
Patients with duodenal ulcer have, on average, increased basal se- 
cretion of acid.” The mechanism responsible for increased basal se- 
cretion is not known, but because basal secretion results from back- 
ground vagal and histamine stimulation, abnormalities in these two 
mechanisms have been hypothesized. Duodenal ulcer patients also 
demonstrate a larger and more prolonged acid secretory response 
to a meal than normal,‘” suggesting either an increased sensitivity to 
acid secretagogues released by meal stimulation or defects in feed- 
back inhibition of acid secretion. As a group, patients with duodenal 
ulcer have an increased secretory capacity for gastric acid. For ex- 
ample, in response to intravenous histamine, the mean peak acid 
secretion in patients with duodenal ulcer is about 40 mEq of HCl 
per hour, while the mean maximal acid output in normal men is 
approximately 20 mEq/hr.” However, there is considerable overlap 
in acid secretion between duodenal ulcer patients and normal sub- 
jects, and most patients with duodenal ulcers fall within the range 
of values for normal. The increased maximal acid output noted in 
patients with duodenal ulcer may, in part, be due to increased num- 
bers of parietal cells15’1” since patients with duodenal ulcer have an 
average of 1.8 billion cells in their fundic mucosa, about twice the 
number of normal subjects. 
Disturbances in gastric emptying have also been demonstrated. 
Some patients with duodenal ulcer have accelerated emptying of 
gastric content, particularly liquids, and duodenal acidification fails 
to slow emptying appropriately.” Recently, normal subjects and pa- 
tients with duodenal ulcer were studied before and after a standard 
meal. Mean intraduodenal pH levels were lower and remained below 
4.0 for an increased proportion of time in the patients with ulcers.” 
In patients with ulcer disease, the total acid exposure of the duo- 
denal mucosa after a meal could be several times that of normal 
subjects.” 
No striking endocrine abnormalities have been demonstrated in 
patients with duodenal ulcer. Basal gastrin levels are not elevated 
and antral gastrin content is normal. Patients with duodenal ulcer 
tend to release more gastrin after protein meal stimulation, and 
acidification of the antral lumen is less effective in inhibiting gastrin 
release. As with acid secretion studies, there is significant overlap 
with normal subjects. These defects in gastrin release do not seem 
to be crucial in the development of duodenal ulcers, however. 
There is no evidence that altered secretion of inhibitory peptides, 
including somatostatin, is associated with the development of duo- 
denal ulceration. Intravenous somatostatin inhibits gastrin release 
and suppresses acid output similarly in ulcer patients and in normal 
subjects.” Although patients with duodenal ulcers have normal 
plasma levels of somatostatin, they have reduced tissue levels of so- 
matostatin and decreased numbers of somatostatin-containing cells 
in antral mucosa.21 The significance of these observations remains to 
be determined. 
Increasing attention has focused on mucosal defense mechanisms 
in the pathogenesis of peptic ulcer. Because many patients with 
duodenal ulcer secrete acid and pepsin at a rate similar to normal 
subjects, it is tempting to postulate that they have a defect in mu- 
cosal resistance to acid and pepsin. Most studies of human mucosal 
defenses in peptic ulcer have focused on mucosal prostaglandin or 
bicarbonate production. Both in animals and in humans, prostaglan- 
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dins have been shown to inhibit gastric acid secretion and to accel- 
erate healing of established duodenal ulcersz2 Gastric mucosal pro- 
duction of prostaglandin E, is decreased in patients with active ulcer 
disease, and prostanoid synthesis is increased in healing ulcers pro- 
duced by cimetidine.‘3 Whether decreases in mucosal prostanoid 
content or synthesis cause peptic ulceration or result secondarily 
from the associated mucosal damage is controversial. Further inves- 
tigation will be required to define the role of mucosal prostaglandins 
in the pathogenesis of duodenal ulcer; the subject is an exciting area 
of research. 
Another postulated mucosal protective mechanism is bicarbonate 
secretion by the gastric and duodenal mucosas. Compared to acid 
secretion, the amount of bicarbonate secreted by the gastric mucosa 
is minimal. Because bicarbonate is secreted beneath the mucous gel 
layer, a small amount is capable of maintaining the pH of the surface 
mucous cells near neutrality even in the presence of low luminal 
pH. Studies by Isenberg and associates have suggested that defective 
duodenal bicarbonate secretion may exist in patients with duodenal 
ulcer.24 In contrast, Blair and colleagues have concluded that gastric 
bicarbonate secretion is normal in patients with duodenal ulcer.25 
Abnormalities in mucosal bicarbonate secretion have no proven 
pathogenetic significance at the present time. 
HISTAMINE BLOCKERS 
CELLULAR MECHANISMS 
Histamine has been recognized for several decades as a potent 
stimulus of gastric acid secretion. Histamine is secreted directly into 
the interstitial fluid by cells within the fundic mucosa and reaches 
neighboring parietal cells by diffusion. Histamine is released in re- 
sponse to a number of physiological stimuli, and blockade of hista- 
mine receptors inhibits most forms of stimulated acid secretion. In 
humans, histamine activation of parietal cells is of central impor- 
tance in gastric acid production. 
There are two classes of histamine receptors. H, receptors are ac- 
tivated selectively by the histamine agonists such as Z-methylhista- 
mine and are blocked by classic antihistamines such as pyrilamine 
maleate. H, receptors, which are distributed widely in the body, are 
stimulated by selective agents such as 4-methylhistamine, and are 
blocked selectively by Hz-receptor antagonists such as cimetidine.26 
H, receptors on gastric parietal cells mediate stimulation of acid se- 
cretion, Hz receptors in the uterus mediate relaxation of uterine 
smooth muscle, and H, receptors in the heart increase contraction 
of atria1 cardiac muscle. 
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Cimetidine, ranitidine, and the newer second generation H,-recep- 
tor antagonists bind competitively to parietal cell H, receptors, pro- 
ducing a potent but reversible inhibition of acid secretion. Because 
H, receptors are also found in nongastric tissues, relatively nonselec- 
tive HZ-receptor antagonists such as cimetidine or ranitidine may 
also exhibit nongastric actions by binding to androgen receptors, to 
receptors of the hepatic microsomal oxidase system and to recep- 
tors on lymphocytes.“7-2Y In addition, both cimetidine and ranitidine 
cross the blood/brain barrier and bind to receptors in the central 
nervous system.30,31 It is hoped that greater binding specificities of 
the newer HZ-receptor antagonists will be reflected by a smaller 
number of clinically significant extragastric side effects. 
CHEMISTRY 
Histamine,-receptor antagonist compounds currently represent 
the most useful class of drugs for the treatment of duodenal ulcer 
disease and for clinical conditions characterized by gastric acid hy- 
persecretion. The first HZ-receptor antagonists developed closely re- 
sembled histamine in chemical structure (Fig 4). The prototype H,- 
receptor antagonist, burimamide, never achieved clinical usefulness 
because of a lack of adequate oral bioactivity. The second compound 
tested, metiamide, demonstrated oral activity but was quickly with- 
drawn from clinical trials because of associated agranulocytosis. The 
third compound tested, cimetidine, shares the imidazole ring of his- 
tamine. Oxmetidine and etintidine, two drugs currently under de- 
velopment, also contain an imidazole ring with different side chain 
substitutions. The second clinically important HZ-receptor antago- 
nist, ranitidine, was the first effective histamine antagonist with an 
alkyl furan ring replacing the imidazole ring of native histamine. 
Subsequent studies have demonstrated that HZ-receptor antago- 
nism can also be produced by compounds that do not closely 
resemble the histamine molecule structurally. Representative 
members of the ever-expanding list of compounds include famo- 
tidine, tiotidine, and the long-acting HZ-receptor antagonists, lox- 
tidine and lamtidine. 
As a result of these molecular rearrangements, a series of com- 
pounds has been produced with increasing potency and efficacy. In 
addition, the pharmacokinetics have been modified so that H,-recep- 
tor antagonism has been prolonged up to and beyond 24 to 48 
hours. In addition, some of the newer compounds display very tight 
binding to receptors with an almost insurmountable antagonism. 

























































































































































































































CIMETIDINE AND RANITIDINE 
Z’h!ARA4ACOZUNETZCS 
The pharmacokinetics of single doses of cimetidine and ranitidine 
have been studied after intravenous and oral administration in nor- 
mal subjects and after oral administration in patients with duodenal 
ulcer. Steady-state pharmacokinetics have also been reported in nor- 
mal subjects and patients with duodenal ulcers receiving therapeu- 
tic doses of the drugs. Except for a modest difference in effects on 
hepatic microsomal enzymes, the pharmacokinetics of ranitidine are 
generally quite similar to those of cimetidine. From a pharmacoki- 
netic standpoint, the choice between these two agents is quite arbi- 
trary. 
Plasma concentrations of cimetidine and ranitidine peak 1 to 3 
hours after oral ingestion3”“” The mean bioavailability of 200 mg of 
oral cimetidine ranges from 63% to 78%. A wider range of values are 
reported for the bioavailability of orally administered ranitidine, 
varying from 39% to 87%. The elimination half-life of intravenously 
administered cimetidine has been reported to be 2.1 to 3.1 hours. 
Ranitidine has a slightly shorter elimination half-life after intrave- 
nous administration of 1.6 to 2.1 hours. Total plasma clearance is 
similar for both drugs, averaging approximately 600 mUmin. Both ci- 
metidine and ranitidine, along with their products of metabolism, 
are secreted in the urine. Approximately 50% of the administered 
dose is recovered unchanged in the urine within 24 hours, with the 
major portion of urinary excretion occurring during the first 6 hours 
after administration. Chronic renal failure significantly prolongs 
plasma clearance.31 A small, but not insignificant, fraction of the 
drug is eliminated in bile. Modest degrees of hepatic dysfunction 
have little effect on elimination of cimetidine or ranitidine; however, 
severe liver dysfunction prolongs the drug half-life. Approximately 
3% of cimetidine is recovered unchanged in the feces. 
Many studies have demonstrated a direct correlation between 
plasma concentration of HZ-receptor antagonists and inhibition of 
intragastric acidity. The 50% inhibition of pentagastrin-stimulated 
gastric acid secretion has been commonly used as one bioassay of 
drug efficacy. The serum concentration of cimetidine that inhibits 
pentagastrin-stimulated acid secretion by 50% (IC,,,) has been stud- 
ied in both healthy subjects and in patients with duodenal ulcers. 
After intraduodenal administration, the I&, of ranitidine was 93.6 
rig/ml in a study reported by Peden et a1.35 Lebert and co-workers 
have reported that the mean peak concentration of ranitidine asso- 
ciated with the 50% suppression of hydrogen ion output was 165 
rig/ml.“” The IC,, of cimetidine is higher. Two well-controlled studies 
on human subjects have reported values of 500 rig/ml and 780 
rig/ml.“‘, 3X The lower IC,, of ranitidine as compared to cimetidine is 
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a reflection of its increased potency. Cimetidine and ranitidine have 
both been shown to suppress basal acid secretion as well as secre- 
tion stimulated (by histamine, peptone, or a standard meal) in a 
dose-dependent manner. 
On a molar basis, ranitidine is six to eight times more potent than 
cimetidine; however, in clinical practice, this difference is not im- 
portant. Equivalent degrees of acid suppression are easily obtained 
with equipotent intravenous doses of these agents (cimetidine 300 
mg every 6 to 8 hours vs. ranitidine 50 mg every 6 to 8 hours). Single 
intravenous doses of cimetidine (300 mgl and ranitidine (50 mg) pro- 
duce equivalent acid suppression in terms of gastric pH, secretory 
volume, titratable acidity, and total acid ouput3’ Both regimens in- 
crease intragastric pH above 3.5 within 30 minutes with maintenance 
at this level for 3 to 4 hours. 
Currently, when oral administration is not possible, most patients 
receive intravenous HZ-receptor antagonists by intermittent bolus 
administration. However, recent evidence suggests that the continu- 
ous infusion of cimetidine is likely to be associated with significant 
advantages. Ostro and coworkers have reported that the primed, 
continuous infusion of cimetidine was more effective than bolus de- 
livery in maintaining serum drug concentrations above 0.5 @ml 
and in keeping gastric pH values above 4.0.“’ Twenty-three patients 
in a medical intensive care unit were examined in this randomized 
crossover trial. In the bolus regimen, patients received 300 mg intra- 
venous cimetidine every 8, 6, or 4 hours as needed to keep gastric 
pH above 4.0. If increasing frequency of dosing was ineffective in 
maintaining the desired pH, the dose was raised to 400 mg every 4 
hours. In the primed infusion regimen, an intravenous bolus of 300 
mg was followed by a continuous infusion of 37.5 mghour. If gastric 
pH was not maintained above 4.0, the infusion rate was increased to 
50, 75, and, finally, 100 mghour. Intragastric pH values were main- 
tained above 4.0 in 87% of patients receiving primed continuous in- 
fusions of up to 50 mghour, while pH values were maintained above 
4.0 in only 22% of patients receiving intermittent boluses of 300 mg 
every 6 hours. Total drug doses were significantly lower with primed 
continuous infusions; in addition, therapeutic serum levels of cime- 
tidine were more easily obtained with this regimen. Serum concen- 
trations of cimetidine typically decreased below the therapeutic 
range of 0.5 kg/ml 4.3 hours after a 300 mg bolus. In contrast, serum 
concentrations of cimetidine were maintained above this level for 12 
hours, when a 300-mg bolus was followed by continuous infusion of 
37.5 mg/hour. 
Pilot studies suggest that administration of cimetidine with total 
parenteral nutrition formulations provides the same pharmacoki- 
netic advantages as primed continuous intravenous infusions. In ad- 
dition, admixture of cimetidine with total parenteral nutrition for- 
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mulations minimizes fluid volume administration. Delivery of 
cimetidine in this fashion requires only 4 to 8 ml of extra fluid per 
day compared to 250 to 500 ml per day when the drug is adminis- 
tered by intermittent boluses 4 times daily. Studies utilizing raniti- 
dine by way of continuous intravenous infusion are currently in 
progress. There is little experience with ranitidine delivered as a 
primed continuous infusion. 
CLINICAL USE 
More than 100 publications have reported the results of open trials 
as well as controlled comparisons of cimetidine or ranitidine with 
placebo or with each other. The evidence is overwhelming that both 
cimetidine and ranitidine are safe and effective agents for the treat- 
ment of patients with duodenal ulcer. The clinical results reported 
for cimetidine and ranitidine have been roughly equivalent; the effi- 
cacy is similar for both compounds when they are administered in 
doses that produce similar reductions in acid output. For most pa- 
tients, and in most clinical circumstances, the drugs have similar 
clinical efficacy (Table 1). 
When endoscopic examination is used to evaluate therapeutic re- 
sults, ulcer healing can be demonstrated in about 70% of patients 
receiving either cimetidine or ranitidine by the end of 4 weeks.“’ By 
8 weeks, 85% to 90% of patients will be ulcer-free and asymptomatic. 
Acute treatment failures, representing the combination of ulcer non- 
healing, patient noncompliance, and drug discontinuance, because 
of side effects, occur in 10% to 20% of patients taking either cimeti- 
dine or ranitidine. Acute treatment failures are slightly higher in pa- 
tients taking cimetidine, representing the slightly higher incidence 
of drug-related side effects. Most studies of chronic maintenance 
therapy with HZ-receptor antagonists have employed either cimeti- 
dine 400 mg or ranitidine 150 mg at night. Ulcer relapse at these 
doses has been reported in approximately 15% to 20% of patients 
receiving cimetidine or ranitidine. Recurrence of peptic ulceration 
TABLE 1. 
Comparison of Cimetidine and Ranitidine in Treatment of 
Peptic Ulceration iW of Patients) 
Results Cimetidine Ranitidine 
Relief of acute pain 75 75 
Ulcer healing at 4 weeks 60-80 60-75 
Ulcer healing at 8 weeks 85-95 SO-90 
Acute treatment failures 20-30 10-15 
Maintenance treatment failures 15-25 10-25 
Posttreatment relapse at 1 year 50 50 
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after cessation of HZ-receptor blockade has been reported in greater 
than half of patients within 1 year, indicating that truly effective 
maintenance therapy means a commitment to continuous life-long 
medication in most patients. 
SIDE EFFECTS 
A variety of side effects have been noted for the currently available 
HZ-receptor antagonists. The overall incidence of adverse effects is 
approximately 476-5s. Most of the clinically significant adverse ef- 
fects result from nonspecific blockade of extragastric H, receptors. 
In addition to the effects of nonspecific blockade, the chronic 
suppression of gastric acid secretion may, at least theoretically, dis- 
rupt normal gastric physiologic functions and predispose to long- 
term complications due to bacterial colonization of the stomach or 
to disturbances of gastric endocrine regulation. In general, both ci- 
metidine and ranitidine cause similar side effects, and, in most in- 
stances, the frequency of complications is similar for the two agents. 
The higher rate of complications reported in the past for cimetidine 
relative to ranitidine probably reflected greater experience with the 
former drug. 
A number of dose-dependent neuropsychiatric effects have been 
reported with the use of cimetidine.JZ-‘” Agitation, confusion, leth- 
argy, and mental depression have been most frequently noted in el- 
derly patients and in those with hepatic or renal dysfunction in 
whom drug metabolism is altered. Significantly increased penetra- 
tion of cimetidine into the cerebrospinal fluid has been reported for 
patients with hepatic disease relative to normal patients. Symptoms 
may reflect interaction of cimetidine with central nervous system 
receptors. When cimetidine administration has been reduced or 
eliminated, symptoms have rapidly disappeared. Significant neuro- 
psychiatric effects reported for ranitidine also rapidly reverse with 
appropriate dose reduction. 
Histamine receptors have been reported on the surface of subpop- 
ulations of suppressor T-lymphocytes and histamine may suppress 
immunologic function. Theoretically, HZ-receptor antagonists could 
augment cell-mediated immunity by blocking these receptors. Ci- 
metidine, but not ranitidine, has been demonstrated in vitro to bind 
to lymphocyte receptors, with subsequent stimulation of cell-me- 
diated immunity.“6 To date, clinically important expression of such 
lymphocyte interactions has not been reported.‘” Agranulocytosis 
and thrombocytopenia, which occur rarely with cimetidine, has also 
been reported with ranitidine.” 
Cimetidine also binds avidly to receptors of the hepatic micro- 
somal oxidase system. As a result of this interaction, cimetidine in- 
creases the blood levels and pharmacologic effects of drugs that de- 
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pend on hepatic metabolism. Such medications include warfarin, 
phenytoin, diazepam, propranolol, theophylline, and chlormethia- 
zole.+“” Dosage adjustments must be made for these and other sim- 
ilarly metabolized drugs when cimetidine therapy is employed. Inter- 
actions with warfarin, theophylline, and phenytoin have been shown 
to be clinically significant. Kanitidine has less effect on hepatic trans- 
formation of therapeutic agents, although it does interact with the ox- 
idase system. In addition to inhibiting the hepatic microsomal en- 
zyme system, cimetidine and ranitidine also decrease hepatic blood 
flow,55. 5ti The decrease in hepatic blood flow caused by these HZ- 
receptor antagonists has been shown to interfere with metabolism 
of drugs such as propranolol and lidocaine, which are cleared by 
the liver. Transient increases in serum transaminase levels have been 
reported in patients receiving both cimetidine and ranitidine. Infre- 
quent reports of possible drug-associated hepatitis have appeared 
for both agents. Animal studies of cimetidine and ranitidine, how- 
ever, have failed to show significant dose-related hepatic toxicity. 
A number of endocrine abnormalities have been reported in the 
patients receiving cimetidine. Cimetidine binds to androgen recep- 
tors, and the intravenous administration of cimetidine consistently 
produces increases in serum prolactin levels.“7 Galactorrhea is oc- 
casionally noted with prolonged use of this medication. Gynecomas- 
tia has been reported in approximately 4% of patients treated with 
long-term high doses of cimetidine.“X Kanitidine is also believed to 
interact with testosterone receptors and seems to possess modest 
antiandrogenic activity. The prolonged use of ranitidine has been 
associated with gynecomastia and impotence. 
SECOND-GENERATION HISTAMINE BLOCKERS 
Currently, a large number of HZ-receptor antagonists are in various 
stages of pharmacological development and clinical testing. These 
compounds represent further refinements in potency, selectivity, 
and duration of action relative to currently available drugs. Famoti- 
dine, the first of the agents, has rapidly achieved clinical acceptance. 
Several more of these agents appear destined for clinical introduc- 
tion in the next several years. 
The first new H,-receptor blocker is famotidine. Famotidine is 
based on a thiazole ring structure in contrast to the imidazole ring 
of cimetidine or the furan ring of ranitidine. Famotidine has the ad- 
vantages of a greater potency and longer duration of action than 
either cimetidine or ranitidine. In normal human subjects, a ZO-mg 
dose of famotidine resulted in 90% suppression of pentagastrin- 
stimulated gastric acid output, compared with a 55% suppression of 
acid output by 300 mg of cimetidine.“” In addition, the duration of 
acid suppression was prolonged relative to the actions of cimetidine. 
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Pentagastrin-stimulated acid secretion was less than 50% of control 
values 12 hours after an oral dose of 20 mg of famotidine. The vol- 
ume of gastric secretion was also significantly decreased. McCallum 
and co-workers have reported that 5 mg famotidine is equipotent 
with 300 mg of cimetidine but with a longer duration of action.6” 
Famotidine has also been demonstrated to inhibit acid secretion 
stimulated by histamine, gastrin, or 2-deoxyglucose. Famotidine 
does not appear to bind to hepatic microsomal enzyme systems as 
avidly as cimetidine and, in contrast to cimetidine, does not affect 
the pharmacokinetics of diazepam (which is eliminated by hepatic 
metabolism1 or procainamide (eliminated by tubular secretion1 .61 
Three large, prospective, controlled studies have compared famoti- 
dine to ranitidine in the short-term treatment of acute ulceration (Ta- 
ble 2). The results were remarkably similar for all three studies.6”-6’ 
Endoscopically documented healing rates of greater than 90% were 
observed at 8 weeks when famotidine was administered at 40 mg once 
per day. Healing rates were not significantly different between pa- 
tients who received famotidine and patients who received ranitidine 
150 mg twice per day. When famotidine was administered at a dose of 
20 mg at bedtime as maintenance therapy, the cumulative U-month 
relapse rate was 23.3% .65 Administration of famotidine at a dose of 40 
mg resulted in a similar 12-month relapse rate of 24.8%, while pa- 
tients treated with placebo had significantly greater ulcer recurrence 
rates (56.8% 1. On the basis of these data, a dose of 20 mg at bedtime 
has been proposed as a maintenance dose for famotidine. The post- 
marketing safety record of famotidine is not as extensive as that of ci- 
metidine or ranitidine.“5 Case reports suggest, however, that the na- 
ture and frequency of adverse effects associated with famotidine will 
be similar to those observed with cimetidine and ranitidine. 
Etintidine, a new HZ-receptor antagonist recently entered into clin- 
ical trials, may circumvent some of the problems associated with 
cimetidine use. Etintidine is structurally similar to cimetidine, differ- 
ing only by the addition of an ethynyl group to the side chain of the 
parent compound. Animal studies have indicated that, on a molar 
basis, etintidine is approximately twice as potent as cimetidine.66 In 
patients with duodenal ulcer disease, a 300-mg dose of etintidine 
was significantly more effective than the same dose of cimetidine in 
suppressing meal-stimulated acid secretion.“’ The mean acid reduc- 
tion at 4 hours after administration of the drug was 94% for etinti- 
dine in comparison to 80% for cimetidine. At these doses, other 
pharmacokinetic parameters were not significantly different. 
The greatest difference between etintidine and cimetidine is illus- 
trated by the dose response curves, which differ in both position 
and slope (Fig 5). The etintidine curve lies to the left of the cimeti- 
dine curve, indicating generally greater potency.67 While greater po- 
tency alone is not therapeutically significant, this difference is ac- 
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PLASMA CONCENTRATION (pgiml) 
FIG 5. 
Clinical pharmacology of etintidine in patients with duodenal ulcer. (Adapted from Brater 
DC, Meyers WM Jr, Dandekar KA, et al: Eur J C/in Pharmacol 1982; 23:495-500.) 
centuated at low plasma concentrations. At low levels, etintidine is 
significantly more effective in suppressing acid secretion than cimet- 
idine. These differences may have practical importance in certain 
clinical circumstances. For example, if the clinical goal is 50% inhi- 
bition of meal-stimulated acid secretion, etintidine is three times 
more potent than cimetidine. This difference might be therapeuti- 
cally beneficial. Alternatively, if the goal is an 80% suppression of 
acid, etintidine is less than twice as potent as cimetidine; the clinical 
value of such a difference is probably minimal. Controlled clinical 
trials will be needed to determine if this drug is superior to cimeti- 
dine or ranitidine in the treatment of patients with active peptic ul- 
cer disease. 
The very extensive clinical experience with cimetidine and raniti- 
dine has demonstrated that these drugs produce similar clinical re- 
sults when administered at doses that produce equivalent acid 
suppression. Neither drug demonstrates total efficacy for the healing 
of acute ulceration or for maintenance of healing. Drug failures prob- 
ably reflect the incomplete suppression of stimulated acid secretion 
by cimetidine or ranitidine. Clinical failures may also be due to a 
lack of effect of Hz-receptor antagonists on gastric mucosal defense 
mechanisms. This lack of complete efficacy has been shared by all 
the Hz-receptor antagonists studied to date. The mechanisms of ac- 
tion of etintidine and famotidine are not different from those of the 
currently employed Hz-receptor blockers and, therefore, these newer 
agents may also share these shortcomings. 
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PROTON PUMP BLOCKERS 
CELLULAR MECHANISMS 
Acid secretion by the parietal cell is due to an enzymatic pump 
which transports hydrogen ions from the parietal cell cytoplasm 
into the lumen of the secretory canaliculus in exchange for potas- 
sium. This hydrogen-potassium ATPase utilizes energy derived from 
the hydrolysis of ATP to transport the hydrogen ions against a steep 
electrochemical gradient. The proton pump is tissue-specific, dem- 
onstrated only in gastric parietal cells. Omeprazole is the first of a 
new class of compounds which selectively blocks this proton 
pump. Because the proton pump represents the terminal stage of 
the acid secretory process, omeprazole effectively blocks all forms of 
stimulated acid secretion-histaminergic, gastrinergic, and cholin- 
ergic .68m7o 
Omeprazole is a weak base with a pK, of 4. The agent is nonreac- 
tive at a neutral pH but becomes activated within the secretory can- 
aliculus at a pH less than 3. In its activated state, omeprazole inter- 
acts with the membrane-bound pump. In addition, because 
omeprazole is a weak base, the drug accumulates in the acidic en- 
vironment of the parietal cell.” Omeprazole has not been demon- 
strated to accumulate in any other organ, nor does it affect any other 
known enzyme systems. When all parietal cell binding sites are oc- 
cupied, acid secretion is completely inhibited; omeprazole is the 
first compound capable of producing true anacidity. 
Omeprazole has not been shown to affect pepsin secretion to the 
same extent to which it inhibits acid secretion.7z This observation is 
consistent with the proposed selective site of action. Small decreases 
in pepsin secretion may be observed during omeprazole therapy; 
however, they are probably secondary to decreased mucosal acid 
secretion or to decreased mucosal metabolic activity. Omeprazole 
does not affect basal or pentagastrin-stimulated intrinsic factor se- 
cretion.‘” 
Short-tern1 treatment with omeprazole results in increased levels 
of circulating gastrin.” Increases in serum gastrin concentrations are 
probably secondary to the pronounced reduction in intragastric 
acidity with concomitant loss of inhibitory feedback by luminal acid 
on the gastrin cell. Serum gastrin concentrations return to normal 
within 1 to 2 weeks after stopping omeprazole therapy. No signifi- 
cant differences have been observed in plasma concentrations of any 
other peptides involved in gastrointestinal function during omepra- 
zole administration. Single oral doses of omeprazole up to 90 mg 
have been demonstrated to have no significant effect on solid or 
liquid gastric emptying rates in patients with duodenal ulcer dis- 
ease.” 
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CHEMISTRY 
Omeprazole is a substituted benzimidazole (Fig 6). 
PHARMACOKINETICS 
Short-term studies in normal subjects have demonstrated that oral 
doses of omeprazole from 20 to 30 mg result in almost complete 
inhibition of maximally stimulated gastric secretion within 6 hours.‘” 
At 24 hours after administration of this dose, 60% to 70% reduction 
in stimulated acid secretion persists.76 Omeprazole administration at 
30 mg once per day reduces nocturnal acidity by approximately 75% 
while 40 mg once daily has been reported to reduce 24-hour median 
acid secretion by almost 100% .7i,i8 Repeated daily doses of omepra- 
zole result in increasing inhibitory action on gastric secretion which 
stabilizes after about 3 days.‘Y,80 
Because of its pKa, omeprazole is slightly soluble in water of neu- 
tral pH, but very soluble in alkaline solutions. Omeprazole is de- 
graded very rapidly in aqueous solutions of low pH and, as a result, 
various oral formulations have been developed to limit intragastric 
degradation. These formulations also serve to improve systemic 
bioavailability. The mean time to attain maximum plasma concentra- 
tions is highly dependent on the formulation of the drug. In general, 
maximal concentrations are achieved between 2 and 5 hours when 
enteric-coated granules of the drug are employed.56 When buffered 
solutions of the drug are employed, bioavailability averages about 
50% ; with the enteric-coated formulations, approximately 65% sys- 
temic availability is achieved.81 The drug is absorbed best when ad- 
ministered on an empty stomach and most studies have employed 







Chemical structure of omeprazole 
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Autoradiographic studies in animals have demonstrated a rapid 
distribution of intravenously administered omeprazole. In rats, after 
4 hours, the drug is detected in appreciable quantities only in the 
gastric mucosa, with trace amounts present in the liver, gallbladder, 
and central nervous system.“” Omeprazole seems to be transported 
in plasma bound to protein. Approximately 95% of the drug is trans- 
ported in association with serum albumin and a-l acid glycoprotein. 
Omeprazole is eliminated rapidly and almost completely by me- 
tabolism. Three metabolites have been identified in human 
plasma-omeprazolesulphone, omeprazolesulfide, and hydroxy- 
omeprazole.‘8 Urinary excretion accounts for 75% to 80% of meta- 
bolic clearance, while approximately 20% is detected in the feces.s3 
Studies in normal human volunteers have demonstrated that ome- 
prazole is eliminated from the plasma with a half-life of between l/z 
and 1% hours. However, while omeprazole dose-dependently inhib- 
its gastric secretion, its antisecretory activity does not correlate with 
peak plasma concentrations. Indeed, in animal studies, omeprazole 
markedly inhibits acid secretion long after plasma levels have de- 
creased below detection limits.XJ This seeming paradox is explained 
by the accumulation and prolonged action of omeprazole at its site 
of action within the parietal cell. 
CLINICAL USES 
Compared with HZ-receptor antagonists, omeprazole accelerates 
ulcer healing and provides superior sVymptomatic relief in patients 
with acute peptic ulceration. Open studies in patients with endo- 
scopically proven duodenal ulcers have demonstrated complete 
healing in 80% of patients after 2 weeks and in 95% of patients after 
4 weeks of treatment with omeprazole at 30 to 40 mg once daily.85 
At doses above 20 mg/day, a significant inhibition of peak acid out- 
put, marked relief of epigastric pain, and decreased need for supple- 
mental antacid therapy have been demonstrated in several studies 
of patients with acute duodenal ulceration. There does not appear 
to be any clinically significant advantage in increasing the omepra- 
zole dose to greater than 20 mg daily. In addition, the inclusion of 
an initial loading dose does not influence the rate of ulcer healing 
or the rapidity of symptomatic relief compared with the same treat- 
ment not preceded by loading dose.86,87 As with most other forms of 
therapy, duodenal ulcers are more difficult to heal in patients who 
smoke compared to nonsmokers. 
Omeprazole 20 to 40 mg daily has been compared with ranitidine 
150 mg twice daily, and cimetidine 1,000 mg/day in patients with 
acute duodenal ulceration. At 4 weeks after initiation of therapy, 92% 
to 100% of ulcers treated with omeprazole were healed by endo- 
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scopic examination.‘l These results are superior to those obtained 
with ranitidine (63% to 78% healing rate) and with cimetidine (45% 
to 84% healing rate). Recently, Tytgat and coinvestigators have re- 
ported that 40 mg daily of omeprazole is highly effective therapy in 
patients with peptic ulcers resistant to cimetidine therapy.” At this 
high dose, omeprazole nearly completely abolished acid secretion. 
At 4 to 6 weeks, 100% of the ulcers in the 10 treated patients were 
healed. 
As is the case for cimetidine or ranitidine therapy, peptic ulcera- 
tion recurs in a high percentage of treated patients after cessation of 
omeprazole therapy. Omeprazole does not affect the underlying ul- 
cer diathesis. Lauritsen and coworkers reported, in patients treated 
with omeprazole, that peptic ulcers recurred in 45W when the drug 
was stopped.“” Walan and associates have reported no significant 
difference in recurrence rates or time of recurrence in patients 
treated initially with either omeprazole or ranitidine.‘” To date, no 
studies employing omeprazole for chronic maintenance therapy for 
duodenal ulceration have been reported. Concerns about the safety 
of chronic omeprazole administration account for this lack of long- 
term therapeutic trials. 
SIDE EFFECTS 
Omeprazole inhibits the oxidative metabolism of some drugs by 
the hepatic microsomal enzyme system.” Studies in normal human 
subjects have demonstrated that omeprazole significantly increases 
plasma diazepam concentration and significantly decreases total 
body clearance.” Hepatic clearance of antipyrine 1s reduced by ap- 
proximately 15% .” However, animal studies have suggested that 
omeprazole interference with the hepatic metabolism of drugs is sig- 
nificantly less than that produced by cimetidine. 
Prolonged toxicological studies in various animal species have 
shown that high doses of omeprazole can produce histologic abnor- 
malities in the gastric mucosa. During long-term treatment with 
omeprazole, 40 to 400 mmol/kg per day, mucosal endocrine cell hy- 
perplasia was observed.“3 In some of the treated rats, enterochro- 
maffm-like cells had formed carcinoid tumors. Within some of the 
carcinoid tumors, growth of abnormal endocrine cells was noted 
into the submucosa. Hyperplasia of oxyntic mucosal cells has also 
been observed in dogs and in mice, although in these species the 
differences are much less notable than in rats, and tumor produc- 
tion has not been observed. 
Larsson and coworkers have noted that enterochromaffin-like cell 
hyperplasia in the rat is directly correlated with elevated circulating 
gastrin levels.“J The degree of hypergastrinemia is, in turn, depen- 
dent on the degree of gastric acid inhibition produced by omepra- 
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zole. The currently available data suggest that the hyperplasia of en- 
terochromaffin-like cells is not induced directly by omeprazole, but 
is a physiological response to prolonged hypergastrinemia. Short- 
term treatment with omeprazole does cause elevations in the serum 
gastrin concentrations in patients with duodenal ulcer disease and 
in normal human volunteers, but these increases are not of the mag- 
nitude of those reported in animal toxicology studies. Currently 
available data do not support a carcinogenic risk during short peri- 
ods of treatment for duodenal ulcer patients. In humans, only pa- 
tients with Zollinger-Ellison syndrome have received long-term, con- 
tinuous omeprazole administration. Hyperplasia of gastric endocrine 
cells during long-term therapy for the Zollinger-Ellison syndrome 
has not been observed. However, because of the theoretical disad- 
vantages of long-term chronic anacidity, omeprazole dosages in hu- 
man patients should be titrated to achieve an acid production of 
approximately 10 mEq/hr in the hour preceding the next dose. Total 
anacidity is not necessary for ulcer healing and is probably undesir- 
able. 
Another concern regarding the long-term use of omeprazole has 
been bacterial overgrowth in the achlorhydric stomach. In 10 
healthy volunteers given 30 mg of omeprazole for 14 days, mean noc- 
turnal intragastric acidity was decreased by 75% .85 Significant in- 
creases in bacterial counts and in concentrations of nitrites and ni- 
trosamines were noted. Three days after cessation of the drug, these 
alterations had completely reversed. To date, there have been no 
reports of illness caused by bacterial overgrowth in patients treated 
with omeprazole. 
Because of these findings and other theoretic concerns about the 
potential disruption of gastric physiologic mechanisms by chronic 
anacidity, some workers have expressed reluctance to employ long- 
term maintenance with omeprazole. An attractive alternative might 
be to use omeprazole for short-term (4 to 8 weeksi treatment of 
acute duodenal ulceration. Because no data are presently available 
to support the use of omeprazole maintenance therapy once ulcers 
have healed, maintenance therapy with a long-acting Hz-receptor an- 
tagonist could then be employed chronically. Famotidine, with its 
long duration of action and potential for once-daily administration, 
would be an exciting new agent in such a therapeutic scheme. 
SELECTIW ANTICHOLINERGIC DRUGS 
CELLULAR MECHANISMS 
Anticholinergic agents decrease acid secretion by blocking mus- 
carinic receptors for acetylcholine. In both experimental animals 
and humans, antimuscarinic agents are equipotent with histamine 
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receptor antagonists in inhibiting stimulated acid secretion. How- 
ever, for nonselective anticholinergic drugs such as atropine and 
propantheline bromide, unpleasant side effects such as dry mouth, 
blurred vision urinary retention, tachycardia, and drying of bron- 
chial secretions are frequent. These side effects limit the amount of 
drug that can be administered to humans. For atropine, limiting ef- 
fects usually occur at doses lower than those required to signifi- 
cantly inhibit acid secretion. Currently available anticholinergic 
drugs, in doses tolerable to human subjects, decrease food-stimu- 
lated acid secretion by only 30%, approximately half the decrease 
obtained with HZ-receptor antagonists. Consequent to the introduc- 
tion of cimetidine and ranitidine, anticholinergic agents were vir- 
tually abandoned in the treatment of patients with peptic ulceration. 
Pirenzepine is a selective anticholinergic agent, a member of a new 
class of antimuscarinic drugs that may again permit the use of anti- 
muscarinic agents in the treatment of peptic ulceration. Pirenzepine 
is considered “selective” because it specifically interacts with mus- 
carinic receptors located on postganglionic cholinergic nerves of the 
stomach (M, receptors) and not with the classic M, cholinergic re- 
ceptors of parietal cells, pupil, bladder, or cardiac muscle.““*g7 Re- 
cent investigations have suggested that M, receptors are located 
within the intramural myenteric plexus of the gastrointestinal tract. 
As a result of this receptor selectivity, pirenzepine effectively inhibits 
vagally stimulated acid secretion while causing almost no undesir- 
able cardiac, visual, or urinary side effects.“, ” Pirenzepine does not 
exhibit muscarinic agonist activity nor HZ-receptor blocking activity. 
CZZEMZSTRY 
Pirenzepine is a pyrido-benzodiazepine compound (Fig 7). The 
drug is structurally similar to imipramine. However, unlike imipra- 
mine, it is without central nervous system activity because of poor 
penetration of the blood/brain barrier. 
PHARMACOZUNETZCS 
Like the classic antimuscarinic drugs, pirenzepine demonstrates 
dose-related anticholinergic activity in both animals and in man. 
However, unlike the classical drugs, pirenzepine inhibits gastric acid 
secretion at doses which do not significantly affect salivation, heart 
rate, ocular function, urinary bladder function, or gastrointestinal 
motility. The relatively low nongastric anticholinergic activity of pi- 
renzepine is reflected by the lower incidence of undesirable anti- 
cholinergic side effects in therapeutic trials of the drug. 
In studies involving both animals and man, pirenzepine adminis- 
tered orally, subcutaneously, or intravenously, produced dose-de- 
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FIG 7. 
Chemical structure of plrenzeplne and non- 
selective antlcholinergic drugs. 
pendent inhibition of gastric acid secretion stimulated by pentagas- 
trin, histamine, bethanechol, or a test meal.‘“’ Pirenzepine markedly 
inhibits gastric acid secretion due to vagal stimuli such as sham 
feeding, insulin-induced hypoglycemia, or fundic distention.“’ It is 
somewhat less effective in inhibiting the effects of direct stimuli such 
as histamine and pentagastrinl” As with most anticholinergic 
agents, the reduction of acid secretion produced by pirenzepine is 
due to a decrease in the volume of gastric secretion rather than acid 
concentration.103 In normal control subjects, orally administered pi- 
renzepine at doses of 50 mg and 100 mg reduced total nocturnal 
acid output by 32% and 41%, respectively.“” One hour after a 50-mg 
oral dose, basal gastric acid output was decreased by 71% and meal- 
stimulated acid output was decreased by 51%. Antisecretory activity 
is still decreased by approximately 45% at 4 hours after oral admin- 
istration. 
Intravenously administered pirenzepine has been demonstrated 
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to produce modest decreases in the secretion of pancreatic enzymes 
such as trypsin, lipase, amylase, and chymotrypsin. In addition, a 
modest increase in bicarbonate secretion by the pancreas has been 
noted. Clinically significant alterations in pancreatic exocrine func- 
tion have not been reported, however, nor have clinically important 
alterations in pancreatic endocrine function been observed. Piren- 
zepine does not appear to affect basal or postprandial concentra- 
tions of serum insulin or glucagon. In patients with duodenal ulcer, 
intravenous administration of pirenzepine reduces basal secretion of 
pancreatic polypeptide and decreases the rise in pancreatic poly- 
peptide stimulated by sham feeding.“” Pirenzepine has minimal ef- 
fects on serum gastrin concentrations. Intravenously administered 
single doses of pirenzepine have been reported to significantly de- 
crease the volume of gastric mucous output, but the drug does not 
appear to alter the composition or function of the gastric mucous 
secretion. The clinical significance of these findings relating to gas- 
tric mucous is unknown. A dose-dependent decrease in pepsin out- 
put has also been reported following administration of intravenous 
pirenzepine. 
When administered orally, therapeutic doses of pirenzepine do 
not increase heart rate significantly.*” In patients with duodenal ul- 
cers, a dose-related reduction in salivation has been noted when 
therapeutic doses of pirenzepine were administered intravenously. 
The effect was much less marked and of shorter duration than that 
occurring after equipotent doses of atropine.80 Symptomatic drying 
of the mucous membranes is unusual, however. In a &day compar- 
ative trial, orally administered pirenzepine 50 mg twice daily was 
associated with no ocular symptoms.‘“” Pirenzepine does not 
change intraocular pressure in subjects with open or closed angle 
glaucoma, and, unlike other classic antimuscarinic agents, pirenze- 
pine is not contraindicated in patients with glaucoma. Despite the 
structural similarity of pirenzepine and tricyclic antidepressant 
drugs, pirenzepine does not cross the blood/brain barrier and has 
not been reported to exhibit central nervous system effects.107”oX Or- 
ally administered pirenzepine has not been reported to affect resid- 
ual urinary volume, tone of the bladder wall, or bladder emptying, 
even in patients with symptomatic prostatic hypertrophy. At usual 
therapeutic doses, oral pirenzepine does not slow gastric emptying 
of a liquid or solid meal in normal healthy subjects.lo7’ lo9 Pirenze- 
pine at 25 to 7.5 mg daily has not been reported to have any signifi- 
cant effect on esophageal function in healthy subjects.110 
With oral administration of the drug, peak plasma concentrations 
of pirenzepine are observed 2 to 3 hours after administration. The 
peak plasma concentration is linearly related to the dosage.“’ With 
repeated oral doses in man, plasma concentrations have been re- 
ported to increase for the first few days, but remain constant there- 
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after. No accumulation of the drug has been observed with long- 
term administration. The mean bioavailability of pirenzepine admin- 
istered orally approximates 25% .ll’, ‘13 Bioavailability has been re- 
ported to decrease when the drug is taken with a meal. 
Studies in animals have demonstrated that pirenzepine is distrib- 
uted widely in the body, being found in all organs with the excep- 
tion of the central nervous system. As mentioned previously, piren- 
zepine does not pass the blood/brain barrier. In addition, the drug 
does not appear to pass the placental barrier. No data are currently 
available regarding the excretion of pirenzepine into human breast 
milk. 
Very little pirenzepine is metabolized. By 4 days after oral admin- 
istration, 90% of the administered dose can be recovered in the 
feces; approximately 10% of the dose is excreted unchanged in the 
urine.‘13 Total plasma clearance approximates 250 cc/min. The mean 
plasma half-life of pirenzepine is approximately 12 hours and is not 
influenced by the route of administration. 
CLINICAL USE 
Several studies have demonstrated that pirenzepine accelerates 
the healing of duodenal ulcers. The rate of ulcer healing in most 
studies is clearly dose-related. Ulcers have been reported to heal in 
52% of patients treated with 50 to 75 mg of pirenzepine daily, and 
in 70% of patients treated with 100 to 150 mg per day.gy In a review 
by Carmine and Brogden, duodenal ulcers were noted to heal in 
32% to 75% of patients taking placebos.” In similar studies, in 45% 
to 75% of those treated with less than 100 mg/day of pirenzepine, 
ulcers were healed. However, in 70% to 90% of patients treated with 
pirenzepine 100 to 150 mg/day over a 4-week period, ulcers were 
healed. These authors concluded that pirenzepine at doses of less 
than 100 mg/day was ineffective in treating patients with acute pep- 
tic ulceration. 
Numerous studies have compared relative efficacy of pirenzepine 
and cimetidine in the treatment of patients with acute ulceration. 
Most of these trials have not demonstrated a significant difference 
between the two agents in healing rates. Although results differ from 
author to author, within each study ulcer healing rates are generally 
similar following 4 or 6 weeks treatment with pirenzepine 100 to 150 
mg/day or cimetidine 1,000 mg/day.” Although ultimate healing rates 
are similar for both drugs, symptomatic remission is usually faster 
in patients treated with cimetidine. Pirenzepine 100 mg/day has also 
been demonstrated to be equivalent to ranitidine 300 mg/day in the 
treatment of patients with acute peptic ulceration.“’ 
Two studies have demonstrated that pirenzepine at a dose of 30 
to 50 mg/day was ineffective as chronic maintenance therapy. Re- 
Cur-r Probl Surg, January 1989 37 
lapse rate for patients receiving pirenzepine was not different from 
placebo-treated or untreated patients. Maintenance therapy with 
higher pirenzepine doses has not been reported. 
Because of these considerations, the usual oral adult dose of pi- 
renzepine for the treatment of patients with acute duodenal ulcera- 
tion is 100 mgday in divided doses at bedtime and before the morn- 
ing meal. The total daily dose may be increased to 150 mg/day in 
two divided doses as needed. Pirenzepine may be combined with 
cimetidine or ranitidine, as this combination appears to potentiate 
the antisecretory effects of HZ-receptor blockade. Anticholinergic 
therapy should be continued until ulcer healing occurs, as docu- 
mented by repeat endoscopy at 4 to 8 weeks. 
SIDE EFFECTS 
In short-term control studies, pirenzepine has been demonstrated 
to be an effective and safe drug. Discontinuation, because of un- 
pleasant side effects, is unusual and has occurred in approximately 
2% of patients.” The most frequently reported side effect of piren- 
zepine therapy is dry mouth. This symptom occurs in approximately 
14% of patients receiving 100 to 150 mg/day. The symptom is usually 
of mild-to-moderate severity and requires withdrawal of the drug in 
only 0.5% of treated patients. The incidence of dry mouth is clearly 
dose-dependent and decreasing dosage is usually followed by ces- 
sation of the unpleasant symptom. 
Ocular disturbances, particularly blurred vision, are another anti- 
muscarinic effect of pirenzepine experienced by approximately 1% 
of patients receiving 100 mgday. This side effect is also dose-depen- 
dent; 5.6% of patients taking 150 mg/day will complain of blurred 
vision.115 The symptom is severe enough to require discontinuation 
in approximately 1% of patients at the higher dose range. 
Clinically important effects on the gastrointestinal tract are un- 
usual. In most instances, the relationship to the selective antimusca- 
rinic action of pirenzepine is unclear. While 3.3% of patients com- 
plain of constipation, a similar 3.4% experience diarrhea during pi- 
renzepine therapy.‘15 Only 0.5% of the patients required treatment 
stoppage because of adverse gastrointestinal effects. Central nervous 
system effects are unusual and rarely require termination of treat- 
ment. Other adverse effects, such as skin reactions, allergy, and nau- 
sea, are unusual. Cardiovascular side effects are rare. When piren- 
zepine 100 to 150 mg/day and cimetidine 1,000 mgday were 
compared, the incidence of side effects such as headache, dizziness, 
endocrinologic abnormalities, allergic reactions, and central nervous 
system symptoms was slightly greater with a cimetidine group;‘15 
however, the relative incidence of dry mouth and blurred vision is 
clearly higher in patients receiving pirenzepine. Long-term studies 
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in patients receiving pirenzepine have not reported any clinically 
significant adverse effects, nor have significant abnormalities in lab- 
oratory tests been reported in these patients.l15 
CXTOPROTECTIVE AGENTS 
PROSTAGLANDINS 
The term “cytoprotection” was coined by .Jacobsonllfi and by 
Robert”’ to denote the phenomenon by which the administration of 
prostaglandins confers gastric mucosa protection from ethanol, 
strong acids, strong alkali, or harmful physical agents. In the “cyto- 
protected” animals, the gastric mucosa remains remarkably intact 
after instillation of these agents which normally cause severe dam- 
age.“” In the present context, “c-ytoprotection” is used to mean pro- 
tection of the gastric mucosa from gross or histologic damage. An 
agent is said to have a cytoprotective effect if it protects against dam- 
age at doses that are lower than the threshold dose for inhibition of 
acid secretion. Prostaglandins are one of several classes of com- 
pounds with cytoprotective action (Table 3). 
Chemistry and Pharmacokinetics 
Prostaglandins are 20-carbon oxygenated fatty acids. They are syn- 
thesized from dietary essential fatty acids through the action of cy- 
clooxygenase. This cyclooxygenase pathway also results in the syn- 
thesis of prostacyclin and thromboxanes (Fig 8). All the 
prostaglandins have a cyclopentane ring, and, depending on the 
structure of the ring, they are classified as prostaglandin A, B, C, D, 
E, and F (Fig 9). The compounds also have upper and lower carbon 
side-chains. Depending on the number of double-bonds present in 
the upper and lower side-chains, the prostaglandins are further des- 








Mechanisms of Cytoprotection 
Bicarbonate secretion 
Reduction in H+ back diffusion 
Mucus secretion 
Increased bloodflow 
Rapid renewal of surface epithelial cells 
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Major metabolic pathways of essential fatty acids and the synthesis of prostaglandins 1, 
2, and 3. (From Sontag SJ: Am J Gastroenterology 1986; 81.1021-1028. Used by permis- 
sion.) 
are of the E-type and the important molecules are prostaglandin E- 
l (PGE-11, PGE-2, and PGE-S. Analogues of PGE-1 and the naturally 
occurring PGE-2 have been developed for possible clinical use. To 
date, only three prostaglandin analogues have been subjected to 
double-blind controlled clinical trials. These are Misoprostil (G.D. 
Searle Co.), Enprostil (Syntex Corp.), and Orbaprostil (Upjohn Co.). 
Two mechanisms of action in healing ulcers are proposed for these 
drugs: (1) inhibition of acid secretion (antisecretory effect); and (21 
cytoprotective effect which can occur at doses lower than the antise- 
cretory dose. It appears that antisecretory doses are required to heal 
ulcers, although cytoprotective doses may protect against aspirin in- 
jury. 
Naturally occurring prostaglandins have very short half-lives in the 
blood and are rapidly inactivated by enzymes in human tissue. The 
synthetic prostaglandin analogues resist rapid degradation and, 
when administered orally, are effective in inhibiting acid secretion 


















Prostaglandlns are designated A through F depending on the structure of the cyclopen- 
trene ring of the molecule. Upper end lower side chains are represented by R7 (7 car- 
bons) and R8 (8 carbons). (From Sontag SJ: Am J Gastroenterology 1986; 81.1021-1028. 
Used by permIssIon ) 
stimulated by histamine, pentagastrin or food for up to 2 hours. Al- 
though their precise mechanism of action in inhibiting acid secre- 
tion is unknown, the compounds do not interact with the cell-sur- 
face receptors for histamine, gastrin, or acetylcholine. They also do 
not appear to interfere with the activity of the H+-K’ATPase. 
Clinical Use 
More than 3,000 patients in 20 countries have been enrolled in 
controlled ulcer trials of Misoprostil and Enprostil.“g Misoprostil, 
administered at a dose of 200 mg 4 times daily, causes endoscopic 
duodenal ulcer healing at 4 weeks in 63% of patients, compared to 
the healing rate for cimetidine of 72%.l” In studies comparing En- 
prostil (70 mg, twice daily), duodenal ulcer healing rates at 4 weeks 
were 40% for placebo, 75% for cimetidine, and 80% for Enpros- 
til. lzlllzz In a European study, comparing Orbaprostil with placebo, 
the 4-week healing rates of duodenal ulcer were 67% and 40%, re- 
spectively.‘“” Both Misoprostil and Enprostil have also been shown 
to heal over 80% of gastric ulcers in patients treated for 6 to 8 
weeks.‘2d, ‘25 
In erosive gastroduodenal disease, low doses of prostaglandins 
have been shown convincingly to prevent gastric mucosal damage 
and gastrointestinal blood loss in subjects receiving aspirin and non- 
steroidal antiinflammatory drugs.“‘, ‘Z 
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FIG 10. 
Prostaglandins 1, 2, and 3 are designated by the number of double bonds present In the 
upper and lower side chains. (From Sontag SJ: Am J Gastroenterology 1986, 81:1021- 
1028. Used by permission.) 
The clinical applications and implications of prostaglandin ther- 
apy in patients with acid peptic disease are summarized in Table 4. 
The-major side effect of prostaglandin therapy is diarrhea.“’ Some 
30% to 40% of patients will experience some loosening of their stool 
but frank diarrhea occurs only in about 5%. The diarrhea in most 
cases has been transient and has stopped despite continued admin- 
istration of the drug. In less than 0.5% of patients, prostaglandin 
analogues have to be stopped because of severe diarrhea. 
The other two side effects of prostaglandins are uterine bleeding 
and the potential for spontaneous abortions. In a West German 
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PGE-2 IEnprustil, Orbaprostilt 
Mechanisms of Action 
Inhibition of acid secretion 
“Cytopmtection” 
Clinical Efficacy 
Similar to H,-receptor 
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PGE-1 = pmstaglandin E-l 
study in which 56 women received two 400-mg doses of Misoprostil 
5 hours apart on the evenings before a scheduled abortion, 6 (11%) 
had partial or total abortion.“’ This potential abortifacient property 
of prostaglandins is of major concern both in terms of danger to 
pregnant women and in terms of potential abuse by those wanting 
to terminate pregnancy. 
COATING AGENTS 
Colloidal Bismuth Compounds 
Tripotassium dicitrate bismuthate, a colloidal bismuth compound, 
has been shown in rats to reduce the incidence of acute gastric ul- 
cers induced by restraint, pyloric ligation, histamine, aspirin, or cor- 
tisone.13’ 
Chemistry and Mechanism of Actions 
Colloidal bismuth compounds promote healing by binding to pro- 
tein and necrotic debris at the ulcer base to form a coating im- 
permeable to acid.131 An acid medium is presumably required for 
colloidal bismuth to chelate to the protein components of the ulcer 
bed to create an insoluble coagulum.‘32 Both light and electron mi- 
croscopy have shown an increase in the number of bismuth-laden 
macrophages recruited to the area of injury. The influx of these mac- 
rophages may expedite healing, and the microvilli of epithelial cells 
at the duodenal ulcer edge have been shown to return more quickly 
to their normal size in patients treated with bismuth as compared 
to patients treated with cimetidine. 
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In addition to the protective coagulum which colloidal bismuth 
compounds form in the ulcer bed, other beneficial actions of these 
drugs have been cited. Tripotassium dicitratobismuthate has been 
shown to have antipepsin activity and to stimulate the release of 
gastric mucus.106 
Clinical Use 
Colloidal bismuth compounds are not approved for clinical use in 
the United States, and most of the reported trials are from the United 
Kingdom, Europe, Australia, and South Africa, where the com- 
pounds are in general use. In controlled clinical trials, colloidal bis- 
muth compounds have been shown to cause healing rates compa- 
rable to cimetidine.13” The major difference between colloidal 
bismuth and cimetidine is the significantly lower ulcer recurrence 
rate after cessation of bismuth therapy relative to that observed of 
cessation of cimetidine. This observation suggests that colloidal bis- 
muth may be capable of changing the natural history of duodenal 
ulcer disease in a manner not observed with cimetidine. 
Both bictropeptide bismuthate1”“‘135 and tripotassium dicitrato- 
bismuthate have been shown to heal gastric ulcers significantly bet- 
ter than placebo (79% to 90% vs. 30% to 35% at 4 weeks). While there 
is anticipation that colloidal bismuth may provide a more effective 
therapy of gastric ulcer than cimetidine, significantly large clinical 
trials are not available to sustain this assumption. 
Side Eficts 
No serious side effects have been reported with the use of colloi- 
dal bismuth compounds. However, bismuth causes blackening of the 
stools which may be confused with melena. It also causes the 
tongue to turn black. Although innocuous, this side effect is cosmet- 
ically unappealing. 
SUCRALFATE 
Chemistry and Mechanism of Actions 
Sucralfate is the basic aluminum salt of sulfated sucrose. In the 
acid medium of the stomach, it becomes viscous and adheres to 
defective mucosa to form a protective barrier.136 Thus, the ulcer bed 
becomes protected from continuing exposure to acid and pepsin. In 
addition to this barrier action, sucralfate possesses several poten- 
tially beneficial actions: (1) it neutralizes small amounts of acid (1 gm 
of sucralfate buffers 13 mEq of H+ at pH 4.01; (21 it inhibits the action 
of pepsin; (31 it binds bile-salts, leading to their depletion from the 
gastric lumen; 14) it stimulates mucus secretion. Sucralfate is one of 
the drugs said to have “cytoprotective” properties. Whether this 
property is due solely to these listed actions of the drug, or whether 
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it also has additional effects on the rate of renewal of surface epithe- 
lial cells and prostaglandin synthesis, has not been conclusively 
shown. 
Clinical Use 
Sucralfate is the first cytoprotective drug commercially available in 
the United States for the treatment of ulcer. Several studies have 
shown sucralfate therapy to be efficacious in the treatment of duo- 
denal ulcer.ls7 Sucralfate has been demonstrated to heal gastric ul- 
cers better than placebo (50% to 71% vs. 13% to 40% at 4 
weeks) ,138. 13Y Sucralfate therapy has also been shown to be effective 
in preventing gastric ulcer relapse.““, I” 
Sucralfate has been reported to protect against gastric mucosal 
injury by aspirin,“” ethanol,lJ3 and concentrated acid or concen- 
trated alkali.lw In addition, sucralfate has been shown to be as effec- 
tive as antacids in the prevention of stress ulceration in critically ill 
patients.lJ’ The drug has also been used with reported efficacy in 
reflux esophagitis and gastritis. 
Side Efsects 
Side effects are mild and infrequent with the use of sucralfate, oc- 
curring in less than 5% of patients. The reported side effects include 
constipation, dizziness, dry mouth, skin rash, headache, diarrhea, 
nausea, and abdominal discomfort. This safety factor makes sucral- 
fate attractive to medical practitioners for long-term maintenance 
use.lJ’ 
A PERSPECTIVE OF THE IMPACT OF ULCER DRUGS ON 
ULCER SURGERY 
A major decline has occurred in the incidence of surgery for pep- 
tic ulcer disease. Two factors are responsible: a decrease in the in- 
cidence of peptic ulcer disease itself and the introduction of effective 
pharmacologic agents. Of these two factors, the latter has had the 
more significant effect on ulcer surgery, with the decline almost en- 
tirely in elective ulcer surgery. It is only on rare occasions now that 
patients are referred to surgery because of intractability of the dis- 
ease. While elective operations have declined, the number of opera- 
tions performed for complications of peptic ulcer (perforation, 
bleeding, and obstruction1 has remained relatively stable. Many sur- 
geons feel the type of peptic ulcer they are now called on to treat 
operatively is more virulent, with a higher incidence of giant ulcers, 
more severe duodenal deformity, and more extensive penetration 
and inflammation. This clinical impression, however, remains only 
an impression, and there are no clinical studies to support it. The 
challenge for surgeons has now become to mesh the currently avail- 
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able operative therapies to the widening array of effective pharma- 
cologic agents. 
From the patient’s perspective, the most important issue is pain 
control. The currently available HZ-receptor antagonists and newer 
agents such as omeprazole are able to provide relief of pain in the 
large majority of patients (i’O%-90%) within 2 to 4 weeks of initiation 
of treatment. Symptomatic control does not seem to be compro- 
mised by a history of recurrence. Relief of pain should not be 
equated with complete healing of ulceration, however, nor does ab- 
sence of pain eliminate the possibility of complication of ulcer dis- 
ease. 
A high proportion of ulcer patients who bleed do so during a re- 
currence, and patients who have bled once have a higher risk of 
bleeding again. Boyd and colleagues have estimated that the lifetime 
risk of hemorrhage for duodenal ulcer patients who have not had 
surgery and who do not receive maintenance drug therapy approx- 
imates 39% for men and 36% for women.lJ7 In contrast, the overall 
proportion of recurrent ulcers that bleed during maintenance ther- 
apy is approximately 2% during the first year.14’ Thus a strong ar- 
gument can be made, from the standpoint of hemorrhage, for con- 
tinued maintenance drug therapy after initial healing of ulcers. 
Recurrent ulcer hemorrhage of a degree that requires hospitaliza- 
tion, or transfusion, or active endoscopic treatment should be con- 
sidered an indication for operation. Of course, massive hemorrhage 
should always prompt consideration for operative intervention. 
Although perforation is less common than hemorrhage, the rate of 
perforation has not decreased markedly since the introduction of 
effective HZ-receptor therapy. The lifetime risk of perforation for un- 
treated patients approximates 10% .14’ Ulcer perforation appears to 
be rare during maintenance therapy for individuals without a history 
of antecedent perforation. However, perforation remains an indica- 
tion for definitive anti-ulcer surgery for those patients with historical 
or anatomic evidence of chronic peptic ulcer disease. 
The reported incidence of symptomatic pyloric stenosis is vari- 
able, but may approximate 10% in untreated individuals. None of the 
agents reviewed can be expected to have beneficial effect on the 
chronic cicatrization causing pyloric obstruction. Pyloric stenosis re- 
mains a firm indication for operative intervention. 
With the decline of peptic ulcer surgery, surgical residents have 
less opportunity to learn all the details of vagotomy or gastric resec- 
tion. The introduction of proximal gastric vagotomy in the treatment 
of duodenal ulcer coincided with the sharp decline in ulcer surgery. 
As a result, many surgical residents complete their training without 
a broad exposure to anti-ulcer surgery. As mentioned previously, the 
major effect of the advent of potent ulcer drugs has been on elective 
and not emergency operations for the disease. It is possible that this, 
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too, may change in the future. As better and safer cytoprotective 
drugs are discovered, the natural history of peptic ulcer in individual 
patients treated will be altered. Such drugs also may be more effi- 
cacious in maintenance therapy. Both of these factors may contrib- 
ute to lowering the incidence of complications in peptic ulcer dis- 
ease and, hence, emergent surgery for peptic ulcer. 
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